Haleon Reports Full-Year Revenue of £11.2bn, Launches £500m Buyback

Haleon reported a 2024 revenue of £11.2bn, a slight decline of 0.6%, but achieved organic growth of 5%, driven primarily by price increases. The company's adjusted operating profit rose by 9.8% to £2.5bn, reflecting strong performance in its key brands like Sensodyne and Centrum. Despite challenges in the pain relief sector, 71% of Haleon's business gained or maintained market share, indicating robust brand strength. The firm generated £1.9bn in free cash flow and reduced its net debt to £7.9bn, while also proposing a 10% increase in dividends and allocating £500m for share buybacks in 2025. Looking ahead, Haleon anticipates organic revenue growth of 4-6% for 2025, with an expectation that profit growth will outpace revenue growth. CEO Brian McNamara expressed satisfaction with the company's progress and competitiveness in the consumer healthcare market.